InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 09/17/2020 4:00:17 PM

Thursday, September 17, 2020 4:00:17 PM

Post# of 9930
Breaking News: $PVCT Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

62% 2-year OS; median OS not reached Stable, non-overlapping safety profile Clinical synergy between PV-10 and immune checkpoint blockade Data compare favorably to approved therapies for patient population KNOXVILLE, TN, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) toda...

In case you are interested PVCT - Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PVCT News